|Mr. Leo Ehrlich||Chairman, CEO, CFO, Principal Accounting Officer & Sec.||465.85k||N/A||1958|
|Ms. Jane Harness||Sr. VP of Clinical Sciences & Portfolio Management||365.75k||N/A||1968|
|Dr. W. James Alexander||Consultant||N/A||N/A||1950|
|Mr. Jim Boeheim||Bus. Advisor||N/A||N/A||N/A|
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Innovation Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.